"We're very excited about the talent and technology that are part of the AgriLabs businesses," says Glen Wilkinson, president of Huvepharma, USA. "This acquisition furthers Huvepharma's strategy in creating a balanced portfolio of products and enhancing our presence in the global market. It also enables more rapid commercialization of biological products through Benchmark Biolabs, a subsidiary of AgriLabs and part of the acquisition of companies."
"We're pleased to be part of Huvepharma's global animal health company as this acquisition will provide resources to bring new solutions to veterinarians and producers more quickly. It will also allow us to accelerate the development of the ExactVac DNA vaccine with ENABL adjuvant which represents the next generation of biological innovation in animal health," says Steve Schram, president and CEO of AgriLabs®.
The acquisition includes AgriLabs® product lines including Colostrx® CS and Colostrx® CR; I-Site® XP, MpB Guard® and Pulmo-Guard® PH-M vaccines; the VetGun™ insecticide delivery system; and AgriLabs' custom vaccines business. In addition, the acquisition also includes Antelope Valley Bios, a contract manufacturing business; and the VaxLiant® portfolio of novel adjuvants - all based in Lincoln, Nebraska.
Both companies will continue operations under their current identities as integration opportunities are identified in 2018.
"Huvepharma and AgriLabs are strong, complementary businesses focused on providing real solutions for the animal food producing industry," Wilkinson says. "This acquisition only strengthens our ability to provide the highest quality products and services as Huvepharma's commitment to serving our customers."
